Ovarian cancer trials

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy is being studied. Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. 2. Female patient, age ≥ 18 years. 3.…. Goal: Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib. Phase/Status/Sponsor: Unknown phase; RECRUITING; North Eastern German Society of Gynaecological Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma is being studied. Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant • Eligibility: Inclusion Criteria: * Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1…. Goal: This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Verismo Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer is being studied. Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +3 • Eligibility: Inclusion Criteria: * Age \>= 18 years NOTE: Because no dosing or adverse event data are currently available on the use of PLX038 in patients \< 18 years…. Goal: This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors is being studied. Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer • Eligibility: Core Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. * Provision…. Goal: This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DESTINY-PANTUMOUR04 is being studied. Conditions: Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer +24 • Eligibility: Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic…. Goal: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers is being studied. Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer • Eligibility: Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 2. Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World…. Goal: This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Have platinum-resistant disease. * Participants who have only had 1 line…. Goal: The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression. Phase/Status/Sponsor: Unknown phase; RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer is being studied. Conditions: Platinum-resistant Ovarian Cancer • Eligibility: Key Inclusion Criteria: * Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. * Participants…. Goal: This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Genmab.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Isoquercetin in People With Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Serous Ovarian Tumor • Eligibility: Inclusion Criteria: * Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with…. Goal: The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer…. Goal: Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is being studied. Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer +2 • Eligibility: * INCLUSION CRITERIA: * For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on…. Goal: Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer is being studied. Conditions: Epithelial Ovarian Cancer • Eligibility: Key Inclusion criteria * Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer. * Participants must have platinum-resistant disease: * Participants who…. Goal: The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels. Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation +3 • Eligibility: Inclusion Criteria: 1. Provide written informed consent; 2. Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment; 3. Has Eastern Cooperative Oncology…. Goal: The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Acerand Therapeutics (Shanghai) Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer is being studied. Conditions: Ovarian Cancer Stage III, Ovarian Cancer Stage IV • Eligibility: Inclusion Criteria: * Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada * Patients fit…. Goal: PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression is being studied. Conditions: Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor • Eligibility: Inclusion Criteria: 1. Written informed consent form (ICF) prior to beginning specific protocol procedures. 2. Female patients ≥ 18 years of age. 3. Eastern Cooperative Oncology Group (ECOG)…. Goal: The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in ovarian cancer (OC) patients with oligometastatic progression (OMP) after first maintenance therapy with any PARP inhibitor. A total of 30 patients with OC and OMP will be enrolled and will receive treatment with niraparib 300 or 200 mg, according to body weight or platelet count. Phase/Status/Sponsor: Unknown phase; RECRUITING; MedSIR.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer is being studied. Conditions: Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer • Eligibility: Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of…. Goal: This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells is being studied. Conditions: Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer +1 • Eligibility: Inclusion Criteria: 1. Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study: 2. Written informed consent and Health…. Goal: The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer is being studied. Conditions: Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria: * Patients must have biopsy-confirmed high grade serous epithelial ovarian cancer. * Patients must present with stage III or IV disease and be appropriate to receive…. Goal: The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons is being studied. Conditions: Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer +1 • Eligibility: INCLUSION CRITERIA: * Individuals born with female sex organs (uterus, ovaries, including cis-gender female and transmasculine individuals, hereafter referred to as "women") scheduled for hysterectomy or bilateral salpingo-oopherectomy…. Goal: BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests LY4066434, a pan-KRAS inhibitor, in people with KRAS-mutant solid tumors. - It includes patients whose tumors have specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) and who have locally advanced, unresectable, or metastatic cancer with measurable disease. - The trial will evaluate LY4066434 alone or with other treatments to see if it is safe and tolerable, using two parts: monotherapy dose escalation and dose optimization, over up to about 5 years. - Key exclusions include active CNS metastases, significant cardiovascular disease, active hepatitis B or C or untreated HIV, other active cancers, and uncontrolled infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer is being studied. Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer +3 • Eligibility: Inclusion Criteria: 1. Patients must have a pathologic diagnosis of high grade serous or endometroid epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, FIGO stage III or IV…. Goal: Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Phase/Status/Sponsor: Unknown phase; RECRUITING; GOG Foundation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Substudy 1 and 2: Confirmed high or medium folate receptor alpha (FRa) expression by Ventana folate receptor 1 (FOLR1) Assay. * Substudy 1 and 2:…. Goal: Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention is being studied. Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation +3 • Eligibility: Inclusion Criteria: * Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers. * Age at inclusion;…. Goal: The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Medical Center Nijmegen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * \< 30 years of age * Individuals diagnosed with a disorder of sex development who have any risk for malignancy in their gonadal tissue and…. Goal: The "Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation" study is open to a subset of patients with disorders of sex development (DSD) which is associated with the risk of malignancy and a high risk of infertility or sterility. For these patients, experimental gonadal tissue cryopreservation is the only fertility preservation option available. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Colorado, Denver.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer is being studied. Conditions: Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma • Eligibility: Inclusion Criteria: * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy * Patients must maintain…. Goal: This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Phase/Status/Sponsor: Unknown phase; RECRUITING; Emory University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer +2 • Eligibility: Inclusion Criteria: * Having signed the written Informed Consent Form (ICF); * Male or female aged ≥18 years; * Life expectancy ≥12 weeks; * Eastern Cooperative Oncology Group…. Goal: This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Patients voluntarily participate in the study, sign informed consent forms, and have good compliance. 2. After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the…. Goal: This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (NSCLC) and other tumors. The study plans to enroll 20 patients with A/A genotype ovarian cancer for treatment evaluation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zhejiang Provincial People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of DF6215 in Patients with Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Solid Tumor Cancer • Eligibility: Key Inclusion Criteria * Male or female patients ≥ 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * An estimated life…. Goal: A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors; is designed to assess the safety, tolerability, and preliminary efficacy of DF6215 alone or in combination with pembrolizumab in patients with advanced solid tumors. The study is open-label, meaning both participants and investigators are aware of the treatment being administered. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dragonfly Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NYSCF Scientific Discovery Biobank is being studied. Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease +26 • Eligibility: Inclusion Criteria: * Age 30 days or older. * Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control. * Adults…. Goal: The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time. Phase/Status/Sponsor: Unknown phase; RECRUITING; New York Stem Cell Foundation Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer is being studied. Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer • Eligibility: Inclusion Criteria: 1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written informed consent form.…. Goal: The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Best-Link Bioscience, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer is being studied. Conditions: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or…. Goal: A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; TORL Biotherapeutics, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of LNCB74 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer +3 • Eligibility: Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed…. Goal: This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; NextCure, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Newly diagnosed with biopsy verified ovarian cancer or highly suspected to have ovarian cancer (based on all data presented at the gynecological cancer MDT) and…. Goal: Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and restaging. The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT) using histopathology as reference standard, and the diagnostic accuracy will be determined. Phase/Status/Sponsor: Unknown phase; RECRUITING; Aalborg University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer is being studied. Conditions: Efficacy and Safety • Eligibility: Inclusion Criteria: * 18-70years old; * High grade (serous or endometrioid) epithelial ovarian cancers, fallopian tube or primary peritoneal carcinoma; * Patients received at least two lines of…. Goal: Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xing Xie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors is being studied. Conditions: Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent +1 • Eligibility: Inclusion Criteria: 1. patients with advanced ovarian cancer or other cancers with expression of claudin6. 2. Life expectancy \>12 weeks 3. Adequate heart,lung,liver,kidney function 4. Available autologous transduced…. Goal: This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others) Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital of Guangzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors is being studied. Conditions: Hepatocarcinoma, Lung Cancer, Melanoma +7 • Eligibility: Inclusion Criteria: 1. Cytohistological confirmation is required for diagnosis of cancer. 2. Signed informed consent before recruiting. 3. Age above 18 years with estimated survival over 3 months.…. Goal: This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences. Phase/Status/Sponsor: Unknown phase; RECRUITING; Second Affiliated Hospital of Guangzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PPK Study Based on Quantitative Pharmacology in Patients With Pamipril is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: 1. The age of the patient is ≥ 18 years old and less than 80 years old. 2. Receive treatment with pamipalil. 3. The patient signed…. Goal: This is a non-intervention, prospective, one-arm, observational real-world clinical trial. The researchers plan to recruit at least 50 qualified patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Qianfoshan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O) is being studied. Conditions: Ovarian Neoplasm, Depressive Symptoms, Quality of Life • Eligibility: Inclusion Criteria: * Stage 2-4 ovarian cancer * Treated with some combination of surgery, chemotherapy, biologics, maintenance therapy * Within 6 months of completion of initial treatment (continued…. Goal: This study will enroll 120 women living with ovarian cancer following completion of initial treatment. Our objective is to test an intervention designed to provide support during the survivorship transition for this population, who live with a high degree of morbidity related to the illness and its treatment as well as a high risk of recurrence. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer is being studied. Conditions: Platinum-resistant Ovarian Cancer • Eligibility: Key Inclusion Criteria: * Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Key Exclusion Criteria: * Participants…. Goal: This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Stemline Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * For cases: women with a first-time diagnosis of histologically confirmed epithelial ovarian or fallopian tube cancer. * For Controls women with no concomitant or past…. Goal: The goal of this observational study is to evaluate whether polygenic risk score (PRS) assessment can help predict the onset of epithelial ovarian cancer in women aged over 18, comparing those with a histologically confirmed diagnosis of epithelial ovarian or fallopian tube cancer (cases) to women with no personal history of ovarian cancer (controls). The main questions it aims to answer are: * Is there an association between PRS and the presence of epithelial ovarian cancer? Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Measuring Oncological Value of Exercise and Statin is being studied. Conditions: Prostate Cancer, Breast Cancer, Kidney Cancer +9 • Eligibility: Inclusion Criteria: * The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is…. Goal: The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery is being studied. Conditions: Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer +1 • Eligibility: Inclusion Criteria: 1. Signed written Informed Consent (in participant's preferred language or short form, per SOP04). 2. Age\>/= 18 years of age or older. 3. Histologically confirmed Stage…. Goal: The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic…. Goal: The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib is being studied. Conditions: Ovarian Cancer, Breast Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated, written ICF. 2. Patient is currently deriving clinical benefit, as judged by the Investigator, from continued treatment in an AZ…. Goal: The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer is being studied. Conditions: Ovarian Neoplasms, Peritoneal Neoplasms • Eligibility: Inclusion Criteria: 1. Age: Women aged 19-85 years. 2. Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer. 3. Platinum Status: * Refractory: Disease progression during platinum-based chemotherapy.…. Goal: The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Seoul National University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: This prospective, multicenter, open-label, randomized phase II maintenance study is evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after platinum combination therapy for BRCAwt patients with relapsed ovarian cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nordic Society of Gynaecological Oncology - Clinical Trials Unit.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Platinum-resistant Ovarian Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma according to WHO Classification of tumours that is advanced/metastatic/recurrent or unresectable and…. Goal: A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy. The study will be offered to ovarian cancer patients whose disease is platinum chemotherapy resistant . Phase/Status/Sponsor: Unknown phase; RECRUITING; British Columbia Cancer Agency.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer is being studied. Conditions: Recurrent Epithelial Ovarian Cancer • Eligibility: Inclusion Criteria: * Pathologically confirmed epithelial ovarian cancer * Should have completed standard treatment for the primary tumor initially. (In the case of advanced ovarian cancer, maximal debulking…. Goal: Rationale Ovarian cancer is the 3rd most common gynecologic malignancy in Korea. The standard treatment is tumor debulking surgery with or without adjuvant chemotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yonsei University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer is being studied. Conditions: High Grade Serous Ovarian Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically proven high grade serous ovarian cancer refractory to conventional treatment, or for which no conventional therapy exists or is declined by the…. Goal: Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Phase/Status/Sponsor: Unknown phase; RECRUITING; Institute of Cancer Research, United Kingdom.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor +2 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. For subjects with GCTs, age ≥15 years * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or…. Goal: The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer is being studied. Conditions: Ovarian Neoplasms • Eligibility: Inclusion Criteria: * Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV * Partial and complete response to treatment with QTNA after 3-4…. Goal: This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Instituto Nacional de Cancerologia de Mexico.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer is being studied. Conditions: Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: 1\. Female subjects aged 19 years or older at the time of obtaining written informed consent. 2\. Patients with advanced high-grade ovarian cancer harboring a BRCA…. Goal: A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Daewoong Pharmaceutical Co. LTD..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery is being studied. Conditions: Epithelial Ovarian Cancer, Rectosigmoid Cancer Metastatic • Eligibility: Inclusion Criteria: * Epithelial ovarian cancer * Negative colonoscopy ( no mucosal involvement) * Intraoperative confirmed serosal or seromuscular rectosigmoid infiltration * ECOG \<3 * ASA \<3 Exclusion…. Goal: Ovarian cancer is the most common cause of death in gynecological cancer. Approximately 75% of epithelial ovarian cancers are detected at an advanced stage. Phase/Status/Sponsor: Unknown phase; RECRUITING; Cukurova University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APG-2449 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer +2 • Eligibility: Inclusion Criteria: 1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and…. Goal: APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ascentage Pharma Group Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cell-free DNA in Hereditary And High-Risk Malignancies 1 is being studied. Conditions: Hereditary Cancer Syndrome • Eligibility: Inclusion Criteria: 1. Individual with any known or suspected hereditary cancer predisposition (i.e. individuals with an identified pathogenic or likely pathogenic variant in a cancer predisposition gene and/or…. Goal: The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Scalable Communication Modalities for Returning Genetic Research Results is being studied. Conditions: Hereditary Breast and Ovarian Cancer, Lynch Syndrome • Eligibility: Inclusion Criteria: -Women in the BWHS previously included in the targeted breast cancer sequencing project Exclusion Criteria: * Women with known cognitive impairments * Women with variant of…. Goal: Efforts to examine the utility of alternate modalities for genetic results disclosure has widespread implications for how precision medicine research might yield direct health benefits for study participants. This study will examine the efficacy of an online self-guided program to return genetic results to a racial minority cohort population. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Boston University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring is being studied. Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma +2 • Eligibility: Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants…. Goal: The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Carevive Systems, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology is being studied. Conditions: Gynecologic Disease, Gynecologic Cancer, Endometriosis +5 • Eligibility: Inclusion Criteria: 1. Subject of legal age (according to local legislation) and at least 18 years old 2. Subject (and if applicable her legal representative) having dated and…. Goal: GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva. The study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian/cervical/uterine cancer) and asymptomatic females. Phase/Status/Sponsor: Unknown phase; RECRUITING; ZIWIG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed diagnosis of epithelial ovarian cancer * Patients received biopsy or puncture to obtain tumor tissues or malignant effusion * Patients…. Goal: The present study aims to collect early bright field image of patient-derived organoids with ovarian cancer. By leveraging artificial intelligence, this study will seek to construct and refine algorithms that able to predict growth of ovarian cancer organoids. Phase/Status/Sponsor: Unknown phase; RECRUITING; Chongqing University Cancer Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor +11 • Eligibility: Inclusion Criteria: Patients eligible for inclusion in this study have to meet all of the following criteria: * Patients, 18 years of age or older * Competent and…. Goal: The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centro di Riferimento Oncologico - Aviano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds is being studied. Conditions: Colorectal Cancer, Sarcoma, Brain Tumors +2 • Eligibility: Inclusion Criteria: 1. Newly diagnosed individuals with stages I-IV colorectal or ovarian cancer, grade 1 and 2 endometrial cancer, as well as those with brain tumors or sarcoma.…. Goal: The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endometrial cancer, and ovarian cancer). The focus will be on assessing changes in lipid mediator concentrations, TAM reprogramming, and immune cell function in treated versus untreated patients. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations is being studied. Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation +11 • Eligibility: Inclusion Criteria: 1. Women must be ≥ 30 and ≤ 50 years of age. 2. Premenopausal women with a documented deleterious mutation in one of the following ovarian…. Goal: This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO) is surgery to remove the fallopian tubes and ovaries at the same time. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is being studied. Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer +13 • Eligibility: Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement * For patients enrolled via…. Goal: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study is being studied. Conditions: Ovarian Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: The goal of this phase 2 clinical trial is to learn if the three treatments olaparib, durvalumab and bevacizumab can treat participants with a diagnosis of stage 4 high grade serous ovarian cancer that is too advanced to undergo upfront surgery. The main questions it aims to answer are: Is the treatment able to shrink the cancer sufficiently for participants to undergo surgery? Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; British Columbia Cancer Agency.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer is being studied. Conditions: Platinum-resistant Recurrent Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Voluntary signing of a written ICF. 2. Age ≥18 years, ≤75 years, female. 3. The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0…. Goal: * Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. * Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; West China Second University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction is being studied. Conditions: Breast Reconstruction, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2) +1 • Eligibility: Inclusion Criteria: * Women aged 18 years and older * Candidates who have already been selected to undergo nipple sparing mastectomy and immediate implant reconstruction by the breast…. Goal: This study is being carried out to better understand how different types of mastectomy surgeries affect women's recovery, satisfaction, and overall well-being after breast cancer surgery and reconstruction. There are different ways to perform a mastectomy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Beaumont Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer is being studied. Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 +27 • Eligibility: Inclusion Criteria: * FOCUS GROUP: Women seen at the MD Anderson Oncofertility Clinic and Adolescent and Young Adult Program who are 18-45 years old at the time of…. Goal: This study develops infertility survey among reproductive age women with gynecological and breast cancer. This study aims to learn how women consider whether or not to try to have a baby after surviving cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is being studied. Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer +10 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 at the time of screening * Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and…. Goal: This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors is being studied. Conditions: MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma +28 • Eligibility: Inclusion Criteria: 1. Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression…. Goal: This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SOLTI Breast Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a combination treatment using oral nilotinib and paclitaxel given by IV and injected into the abdomen for people whose peritoneal carcinomatosis cannot be removed with surgery. Researchers want to know if this bidirectional chemotherapy can shrink tumors enough to make surgery possible. Participants are adults 18 and older with peritoneal carcinomatosis from colorectal, appendiceal, small bowel, gastric, cholangiocarcinoma, breast, ovarian, or other gynecologic cancers who have not responded to at least one line of standard chemotherapy and are not candidates for complete cytoreduction. It is a Phase II open-label, non-randomized study designed to give up to six cycles and use laparoscopy to restage tumor response. Key exclusions include allergies to study drugs, recent intraperitoneal chemotherapy or major abdominal surgery, medications that prolong the QT interval or strongly inhibit certain drug-metabolizing enzymes, pregnancy, and certain HIV treatment conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genetic Testing in African Americans is being studied. Conditions: Ovarian Cancer, Endometrial Cancer, Peritoneal Cancer • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years of age. 2. New diagnosis of ovarian, endometrial, fallopian, or primary peritoneal carcinoma. 3. Diagnostic procedure performed at AU Health Medical…. Goal: This is a pilot/feasibility study to conduct genetic testing using tumor/blood samples of African American and Caucasian patients with ovarian and endometrial cancer following surgery at AU Health Medical Center. The aim of the pilot/feasibility study is to sequence a panel of cancer genes on paired tumor/blood (germline) samples of patients with ovarian and endometrial tumors at a two-week time point following surgery at AU Medical Center. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Augusta University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Living WELL: A Web-Based Program for Ovarian Cancer Survivors is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Survivors 18 (19 at UNMC since age of Majority is 19 in Nebraska) years or older with a cytological or histological diagnosis of any stage…. Goal: The purpose of this study is to determine the efficacy of a group-based and web-delivered psychosocial intervention for ovarian cancer survivors (Mindful Living \[ML\]) compared to a health promotion condition (Healthy Lifestyles \[HL\]) in increasing health related quality of life (HRQOL) and decreasing perceived stress (primary aim), and decreasing anxiety, depressive mood, and fatigue (secondary aims) across a 12-month period. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Susan Lutgendorf.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC) +2 • Eligibility: Inclusion Criteria: * Phase 1 Dose Escalation cohorts, Phase 1 Backfill cohorts, and Phase 2 Tumor Type-Specific cohort(s): must meet one of the following criteria: * HER2- metastatic…. Goal: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Nuvation Bio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests botensilimab, an Fc-engineered anti-CTLA-4 monoclonal antibody, alone and in combination with balstilimab (anti-PD-1) in advanced solid tumors to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, and to identify the maximum tolerated dose and the recommended Phase 2 dose. - It is for adults with refractory, advanced cancers and will enroll up to about 550 evaluable participants across multiple cancer types, including NSCLC, melanoma, hepatocellular cancer, and others. - The trial uses a 3+3 dose-escalation design to determine dosing and will also explore safety, PK/PD, and potential clinical activity at doses deemed potentially effective. - Key exclusions include active brain metastases unless treated with specific criteria, active autoimmune disease requiring systemic therapy, active infection, pregnancy or breastfeeding, and certain recent or concurrent cancer therapies (prior CTLA-4 therapy may be allowed in some indications with sponsor agreement).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma +9 • Eligibility: Key Inclusion Criteria: * Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic…. Goal: This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cybrexa Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial is being studied. Conditions: BRCA Mutation, Estrogen Deficiency, Surgical Menopause +3 • Eligibility: Inclusion Criteria: * Women between 18-40 years old; * BRCA1/2 germline mutations; * Completed childbearing; * Willing to undergo RRSO; * Negative final histological examination; * No previous…. Goal: Selecting theca and granulosa cells from removed ovaries of BRCA1/2mut patients undergoing Risk-reducing salpingo-oophorectomy (RRSO) and developing a 3D bioprinted hormone-producing bioprosthetic model. If efficacy and tolerability are confirmed in vivo, this bioprosthetic model might be used to replace hormones' production in BRCA mutated patients undergoing prophylactic surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Age ≥ 70 years * Histologically or cytologically confirmed diagnosis of advanced ovarian cancer (FIGO stage III or IV) * PARP inhibitors -naive patient who…. Goal: Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Hospices Civils de Lyon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension is being studied. Conditions: Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab +1 • Eligibility: Inclusion Criteria: * women with newly ovarian cancer diagnosis (FIGO III to IV) * age over 18 years old at time of ovarian cancer diagnosis * diagnosed between…. Goal: Antiangiogenic therapies like bevacizumab, have notably improved cancer treatment, including for gynecological cancers, by inhibiting the vascular endothelial growth factor and thus limiting tumor growth. In treating advanced ovarian cancer, bevacizumab has been shown to extend progression-free survival by four months, though it also induces or worsens hypertension in 2 to 19% of patients by affecting vascular nitric oxide production or by capillary rarefaction. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Groupe Hospitalier Pitie-Salpetriere.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes is being studied. Conditions: Ovarian Cancer, Prostate Cancer, Pancreas Cancer • Eligibility: Inclusion Criteria: * MSK patient age 18 years or older. * Diagnosed with or presumed by physician to have prostate cancer, or pancreatic cancer and recommended to undergo,…. Goal: This study will evaluate patients' experiences with having gynecologic or prostate medical oncologists and surgeons offer them genetic testing, and having genetic counselors return the test results to patients over the telephone. This is different from the usual approach to genetic testing, where gynecologic or prostate medical oncologists and surgeons refer their patients to a genetic counselor in order to have these tests done, and the genetic counselors return the test results to the patient in person or over the telephone. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery is being studied. Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer +7 • Eligibility: Inclusion Criteria: 1. Adults 18 years old or older. 2. Newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease. 3.…. Goal: Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; CanariaBio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests pembrolizumab in adults with advanced solid tumors to study gene changes and immune biomarkers during treatment and how they relate to response. Participants are adults 18 or older with unresectable or metastatic solid cancers that are incurable and for whom standard therapy has failed or isn’t available. Some eligible cancer types include head and neck squamous cell carcinoma, triple-negative breast cancer, epithelial ovarian cancer, and malignant melanoma. Exclusions include active infections or immune problems, active CNS metastases, autoimmune disease needing systemic treatment in the past two years, HIV or hepatitis B/C, pregnancy or breastfeeding, prior PD-1/PD-L1 therapy, and recent live vaccines or major cancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Age 18-70 years old (≥18, ≤70); * Open surgery, laparoscopic surgery or coarse needle puncture biopsy and pathology confirmed late in the center of the…. Goal: To further evaluate and observe the efficacy and safety of solantinib combined with METR-NK neoadjuvant therapy for advanced epithelial ovarian cancer in patients with advanced epithelial ovarian cancer by using solantinib combined with METR-NK neoadjuvant therapy Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Anhui Provincial Cancer Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer is being studied. Conditions: Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer • Eligibility: Inclusion Criteria: 1. The participant is willing to give written signed and dated informed consent to participate in the study. 2. Female ≥18 years of age fulfilling all…. Goal: This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with platinum-resistant/refractory recurrent high-grade serous epithelial ovarian cancer. Paclitaxel Lipid Suspension or conventional paclitaxel will be administered intravenously at a dose level of 80 mg/m2 on Day 1, Day 8 and Day 15 of each 28 days cycle. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jina Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reproductive Health Outcomes in Young Patients with Ovarian Cancer After Surgical Treatment: a Retrospective Study is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Women in reproductive age 18-45 yrs 2. Localized ovarian cancer 3. Patients undergoing surgical intervention Exclusion Criteria: 1- Patients who refuse to participate in the…. Goal: Ovarian cancer (OC) is the second commonest gynecological cancer with an overall incidence of 1.4% , associated with high mortality rate , There are three major types of ovarian cancers: epithelial ovarian carcinomas, germ cell tumors, and stromal cell tumors . Ovarian cancer directly affects fertility, as treatment consists of surgical removal of the reproductive system and/or exposure to gonadotoxic agents. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Assiut University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is being studied. Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor +19 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Signed informed consent and willing and able to comply with study procedures and scheduled visits. 3. For Dose Escalation,…. Goal: This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Salubris Biotherapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) is being studied. Conditions: Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms • Eligibility: Inclusion Criteria: * Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. * Has received 1 or 2 prior lines of systemic therapy for ovarian cancer…. Goal: The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\] ≥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for all participants. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) is being studied. Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma • Eligibility: Inclusion Criteria: 1. Women aged ≥ 18 years. 2. Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (diagnosis by biopsy…. Goal: The purpose of this study is to answer the fundamental question, should the physicians choose Surgery or Chemotherapy (SOC-2) in advanced ovarian cancer? Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Shanghai Gynecologic Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer is being studied. Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +31 • Eligibility: Inclusion Criteria: * Women with recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer that have progressed after receiving standard of care therapies or are not…. Goal: This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Precigen, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Phase 1 trial tests an allogeneic cell-based vaccine called DCP-001 to evaluate its safety, feasibility, and ability to trigger an immune response in high-grade serous ovarian cancer patients after finishing primary treatment. Eligible participants are adults with primary HGSOC (FIGO 3B–IV) who completed standard treatment and have CA125 under 35 U/mL; vaccinations start about 6 weeks after the last chemotherapy cycle. Participants will receive 4 vaccinations of 25 million DCP-001 cells, followed by 2 booster vaccinations of 10 million cells, with 24 months of follow-up to monitor safety and immune responses. Key exclusions include active autoimmune disease needing systemic immunosuppressive therapy and uncontrolled infections; no participation in another investigational drug trial within 30 days before enrollment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Asian Multicenter Prospective Study of ctDNA Sequencing is being studied. Conditions: Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma +3 • Eligibility: Inclusion Criteria: 1. Age of 18 years or older at registration. 2. Diagnosis of cancer which is targeted by each cohort. 3. Metastatic and/or recurrent disease. Exclusion Criteria:…. Goal: This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types, analytical methods, participating countries, and participating institutions. Phase/Status/Sponsor: Unknown phase; UNKNOWN; National Cancer Center, Japan.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests NGM438 as a standalone treatment and in combination with pembrolizumab for advanced or metastatic solid tumors, to learn about safety and potential effectiveness. It targets adults whose cancer has progressed after other therapies or who could not tolerate them. Eligible participants need adequate bone marrow, kidney, and liver function and a performance status of 0 or 1. They must have recovered from prior treatment side effects to baseline or to CTCAE Grade 1. A key exclusion is prior treatment targeting LAIR1.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure is being studied. Conditions: Epithelial Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Voluntary participation and signature of informed consent; 2. Age ≥18; 3. Histologically diagnosed relapsed non-mucinous epithelial ovarian cancer (EOC) (including primary peritoneal and/or fallopian tube…. Goal: The PamiAP will be a Phase II, single-arm, open label study to explore the efficacy and safety of Pamiparib treatment in patients with Epithelial Ovarian Cancer（EOC） who have had exposure to prior a PARP (poly(ADP-ribose)-polymerase) inhibitor Phase/Status/Sponsor: Unknown phase; UNKNOWN; Zhejiang Cancer Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 is being studied. Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer +2 • Eligibility: Inclusion Criteria: * Agreement to provide fresh or archived tumor tissue sample within 3 years * Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced…. Goal: This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib). Phase/Status/Sponsor: Unknown phase; COMPLETED; Risen (Suzhou) Pharma Tech Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease is being studied. Conditions: Epithelial Ovarian Cancer • Eligibility: Inclusion Criteria: Clinical diagnosis of epithelial ovarian cancer stage II-IV Exclusion Criteria: Insufficient tumor to perform Signatera testing; Inability to provide consent for the trial. Goal: Blood samples and Tumor tissue will be collected at certain timepoints and will be tested. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

IMX-110 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer +2 • Eligibility: Inclusion Criteria: 1. Male or female patients who are 18 years or older 2. Patients with confirmed advanced solid tumor as per histology, who have progressed, are refractory,…. Goal: Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110. The RP2D will be evaluated in a further dose expansion Phase 2a study submitted. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Immix Biopharma Australia Pty Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan is being studied. Conditions: Cervical Cancers, Endometrial Cancer, Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Adults aged ≥ 18 years when their clinical data are reviewed 2. Patients who fulfill ONE of the following criteria * Imaging or histological diagnosis…. Goal: Trastuzumab Deruxtecan (T-DXd) is a humanized anti-HER2 monoclonal antibody covalently linked to DXd, which is a topoisomerase 1 inhibitor. T-DXd has been approved for the treatment of HER2-positive breast cancer, HER2-mutated lung cancer, HER2-positive gastric cancer, and HER2-low breast cancer in Taiwan. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2) is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: 1. Female ≥18 years of age at Screening Visit. 2. Diagnosed with ovarian cancer, fallopian tube, or primary peritoneal cancer 3. Undergoing active treatment at some…. Goal: This study will evaluate the use of a mobile application in improving the patient-reported health outcome measures (PROMIS) for patients diagnosed with advanced stage ovarian, fallopian tube, and primary peritoneal cancer. The application will incorporate clinical data from the patient's medical chart as well as capture patient-reported outcome measures on an ongoing basis to better inform physicians and the care team so that necessary interventions may be implemented. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jonsson Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer is being studied. Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma • Eligibility: Inclusion Criteria: * Signed and dated Investigational Review Board/Independent Ethics Committee-approved informed consent form (ICF) prior to study-specific screening procedures. * Female patients aged ≥18 years old at…. Goal: This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone. Phase/Status/Sponsor: Unknown phase; COMPLETED; Corcept Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK is being studied. Conditions: Ovary Cancer • Eligibility: Inclusion Criteria: * Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III - IV) epithelial ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer who have…. Goal: This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study is being studied. Conditions: Ovarian Cancer, Adnexal Mass • Eligibility: Inclusion Criteria: * Women undergoing surgery with the Gynecology Service at MSK. * Women undergoing surgery for an adnexal mass without pre-operative suspicion of high stage disease, with…. Goal: The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients is being studied. Conditions: Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma +14 • Eligibility: Inclusion Criteria: \- Exclusion Criteria: \-. Goal: AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Phase/Status/Sponsor: Unknown phase; AVAILABLE; AVM Biotechnology Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1 Study of [225Ac]-FPI-1434 Injection is being studied. Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer +7 • Eligibility: Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated,…. Goal: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent). Phase/Status/Sponsor: Unknown phase; TERMINATED; Fusion Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Be willing and able to provide written informed consent for the trial. * Be ≥ 18 years of age on day of signing informed consent.…. Goal: This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386 Phase/Status/Sponsor: Unknown phase; COMPLETED; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Neoadjuvant Chemotherapy, Prehabilitation • Eligibility: Inclusion Criteria: * Female; ≥ 60 years of age * Diagnosed with ovarian, fallopian tube or primary peritoneal cancer and undergoing planned neoadjuvant chemotherapy and are expecting to…. Goal: The purpose of this study is to test the effectiveness of a home-based, patient-tailored intervention, FIT4SURGERY, to promote physical activity among women with ovarian cancer undergoing neoadjuvant chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Northwestern University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evolution of the Therapeutic Care in Ovarian Cancer From 2011 is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion criteria : * 18 years old female * Female who received surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic procedure) for ovarian cancer…. Goal: The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This database compiles data from existing data available from patient's electronic medical records (EMR). Phase/Status/Sponsor: Unknown phase; SUSPENDED; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer is being studied. Conditions: Recurrent Ovarian Carcinoma • Eligibility: Inclusion Criteria: 1. Patients with histologically diagnosed ovarian, fallopian tube, or primary peritoneal cancer 2. Relapsed disease 3. Patients with up to three prior therapies. In patients with…. Goal: This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse. Phase/Status/Sponsor: Unknown phase; COMPLETED; AGO Research GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery is being studied. Conditions: Ovarian Cancer, Perioperative Blood Loss, Blood Transfusion Events • Eligibility: Inclusion Criteria: * Age 18-60. * Female gender. * Ovarian cancer of \> 12 months duration. * FIGO stage I-III. * American Society of Anesthesiologists (ASA) status 1-3.…. Goal: This study evaluated the effectiveness of a single dose of tranexamic acid compared to a placebo in reducing blood loss and the need for blood transfusions in women undergoing surgery for ovarian cancer. Tranexamic acid, a medication that helps control bleeding by stabilizing blood clots, has been widely used in other surgical settings but has not been well studied in ovarian cancer surgery. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sheikh Zayed Medical College.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spectroscopy in Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Ovarian Neoplasms, Ovary Cyst +1 • Eligibility: Inclusion Criteria: * Female * Symptoms suggestive of ovarian cancer * Patients undergoing treatment of Ovarian Cancer Exclusion Criteria: * Less than 18 years of age * Unable…. Goal: Ovarian cancer is the eighth most common cause of cancer death in the world. Advanced stage at diagnosis is associated with lower survival rates, thus early detection appears to have an important role. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Exeter.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers is being studied. Conditions: HER2-expressing Cancers • Eligibility: Inclusion Criteria: * Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease. * Dose-escalation (Cohort 1):…. Goal: This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Zymeworks BC Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria 1. Japanese female participants aged 20 years or older on the day of signing informed consent. 2. Voluntary written consent must be given before performance of…. Goal: The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4 previous chemotherapy regimens. Phase/Status/Sponsor: Unknown phase; COMPLETED; Takeda.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients is being studied. Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows: * Phase II: extensive stage small cell lung cancer with progression…. Goal: The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. \*\*The Phase 1b portion of the study is now complete\*\*. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cancer Research and Biostatistics Clinical Trials Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers is being studied. Conditions: Gynecologic Neoplasms, Epithelial Ovarian Cancer, Uterine Endometrial Cancer +2 • Eligibility: Inclusion Criteria: 1. Have histologically or cytologically confirmed gynecologic tumor of müllerian origin, specifically epithelial ovarian, fallopian tube, primary peritoneal, or uterine endometrial cancer. 2. Have disease amenable…. Goal: The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; AA Secord.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer is being studied. Conditions: Ovarian Cancer, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria: * Tumor type: \* Biopsy proven serous epithelial ovarian carcinoma or peritoneal carcinoma * Primary or recurrent disease * Extent of disease: * Positive retroperitoneal lymph…. Goal: The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the pharmacokinetics and pharmacodynamics of cisplatin used as (hyperthermic) intraperitoneal chemoperfusion, as an adjunct to surgery, in women with stage III epithelial ovarian cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Ghent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous +6 • Eligibility: Key Inclusion Criteria: * Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma,…. Goal: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xencor, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs is being studied. Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: 1. Subjects treated with TCR-T cell drug product on study TCR001-201 or any other Alaunos TCR-T cell drug product study and have either completed their original…. Goal: Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors Phase/Status/Sponsor: Unknown phase; COMPLETED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests CDX-585 in people with advanced solid tumors to find the maximum tolerated dose and to assess safety, tolerability, and signs of effectiveness. - It uses dose-escalation and expansion phases, with an expansion portion studying safety at the chosen dose in selected tumor types. - Eligible participants are patients with recurrent, locally advanced, or metastatic solid tumors who have had standard therapy and have measurable disease. - Key exclusions include severe allergic reactions to monoclonal antibodies, prior anti-ILT4 or anti-PD-1/PD-L1 therapies, active autoimmune disease or pneumonitis, untreated active CNS metastases, recent thrombotic events, or certain other prior cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors is being studied. Conditions: Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer +9 • Eligibility: Inclusion Criteria: 1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA…. Goal: A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors Phase/Status/Sponsor: Unknown phase; TERMINATED; Alaunos Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible…. Goal: This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion. Phase/Status/Sponsor: Unknown phase; TERMINATED; Actym Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) is being studied. Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria: * Patient is female and ≥18 years of age. * Patient has histologically confirmed diagnosis of EOC (ie, high-grade serous, endometrioid of any grade, clear cell),…. Goal: This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Phase/Status/Sponsor: Unknown phase; TERMINATED; Mural Oncology, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer is being studied. Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative +64 • Eligibility: Inclusion Criteria: * Newly diagnosed patients for the following conditions * Colon cancer stage III and IV * Rectal cancer stage II, III, IV * Glioblastoma multiforme (brain)…. Goal: This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer is being studied. Conditions: Neoplasms • Eligibility: Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid…. Goal: Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer Phase/Status/Sponsor: Unknown phase; COMPLETED; Vincerx Pharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies is being studied. Conditions: Solid Tumors, Cancer • Eligibility: Inclusion Criteria: * The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or metastatic solid tumor of the nine types listed below: * Pancreatic Cancer…. Goal: This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types. Phase/Status/Sponsor: Unknown phase; COMPLETED; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Histologically documented epithelial ovarian, primary peritoneal or fallopian tube carcinoma or high grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma,or…. Goal: This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is previously untreated. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Oklahoma.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers is being studied. Conditions: Breast Cancer, Ovarian Cancer, Pancreatic Cancer +1 • Eligibility: Inclusion Criteria: * Potentially eligible participants will be identified via medical record screening and/or in accordance with their clinical visit. A HIPAA waiver of authorization will be obtained…. Goal: This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk. Phase/Status/Sponsor: Unknown phase; COMPLETED; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests Felmetatug Vedotin (SGN-B7H4V), given alone or with pembrolizumab, to see if it is safe and what side effects it may have in people with advanced solid tumors. It is for adults with locally advanced unresectable or metastatic cancers, including certain ovarian/peritoneal cancers, HER2-negative breast cancer, triple-negative breast cancer, endometrial cancer, some lung cancers, cholangiocarcinoma/gallbladder cancer, and adenoid cystic carcinoma. The trial has five parts to find the right dose, assess safety and activity, study the combination with pembrolizumab, and evaluate safety and efficacy in triple-negative breast cancer. Eligibility includes measurable disease and good functioning (ECOG 0–1) with tumor tissue available; key exclusions are a new cancer within 3 years (with some exceptions), active brain metastases, prior MMAE- or B7-H4-targeting therapy, neuropathy ≥ grade 2, or corneal disease. Status: Terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * female patients, \>/=18 years of age; * epithelial ovarian, fallopian tube or primary peritoneal cancer; * platinum-resistant disease (disease progression within \<6 months of platinum…. Goal: The standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance. Phase/Status/Sponsor: Unknown phase; COMPLETED; Jiangsu Simcere Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 is being studied. Conditions: High-grade Serous Ovarian Cancer • Eligibility: Inclusion Criteria: * Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53 * Disease Progression between 4 weeks - 6 months after the…. Goal: The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. Phase/Status/Sponsor: Unknown phase; COMPLETED; Aprea Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) is being studied. Conditions: Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC +12 • Eligibility: Inclusion Criteria: * Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative…. Goal: This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%. Phase/Status/Sponsor: Unknown phase; TERMINATED; VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a screening study in which no therapy is given, to see if a patient’s tumor mutations and HLA type match Alaunos Therapeutics’ TCR library for potential autologous TCR-T cell therapy in a Phase I/II program. It targets adults with certain advanced cancers (gynecologic ovarian/endometrial, colorectal, pancreatic, non-small cell lung cancer, or cholangiocarcinoma) who have progressed after at least one prior treatment. The study tests somatic mutations and high‑resolution HLA typing to determine if a matching TCR is available; if a match is found, the patient may enroll in the Phase I/II therapy; if not, they are discontinued from this protocol. Exclusions include unstable medical conditions, primary immunodeficiency, active cancers requiring treatment (with limited exceptions), bleeding disorders or chronic anticoagulation, recent organ transplant, or xenotransplantation, and participants must have prior genomic testing or plan biopsy and provide informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors is being studied. Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor +2 • Eligibility: Inclusion Criteria: * Signed informed consent * Subjects must be ≥ 18 years of age ( ≥ 20 years of age for Taiwan site) * Subject with advanced…. Goal: ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702. Phase/Status/Sponsor: Unknown phase; COMPLETED; Acepodia Biotech, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Diagnosis of ovarian cancer or treatment for ovarian cancer through the University of Michigan Gynecologic Oncology service * Completed primary treatment (either surgery alone or…. Goal: In this pilot study, ovarian cancer survivors will be enrolled and followed for six months to evaluate usage of an eHealth app called "Purposeful". Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Michigan Rogel Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer is being studied. Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria: 1. Patients must have histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma per pre-treatment biopsies by laparoscopy, or interventional radiology or CT guided…. Goal: This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Imunon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling is being studied. Conditions: Quality, Prostate Cancer, Gastrointestinal Cancer +3 • Eligibility: Inclusion Criteria: Inclusion criteria for: Limited English Proficiency (LEP), primarily Spanish speaking cohort * Preferred language for receiving medical information is Spanish * Has a personal or family…. Goal: The purpose of this research study is to understand the impact of an educational video or pamphlet on the patient experience in a hereditary cancer genetic counseling program. In order to make this assessment, it is necessary to perform qualitative and quantitative research among patients in a hereditary cancer genetic counseling clinic. Phase/Status/Sponsor: Unknown phase; COMPLETED; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet is being studied. Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma +8 • Eligibility: Inclusion Criteria: * Patients over 18 years of age * Able to tolerate oral diet * Confirmed diagnosis of SBO due to underlying malignancy to include: 1. Patients…. Goal: Bowel obstruction is a common complication in patients with ovarian, peritoneal and bowel cancer due to a mass or spread of disease, causing narrowing to the gut, as these cancers can grow on the bowel surface. Certain foods may lead to symptoms such as pain, bloating, feeling full, feeling sick, vomiting and difficulty passing a bowel motion. Phase/Status/Sponsor: Unknown phase; COMPLETED; Royal Surrey County Hospital NHS Foundation Trust.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer is being studied. Conditions: Advanced Cancer • Eligibility: Inclusion Criteria: * Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer…. Goal: The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.